Q-omics provides the consensus-scored ATP12A profile across patient tissues and cancer cell-line models. ATP12A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP12A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ATP12A RNA expression shows 12,653 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where ATP12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP12A survival associations across molecular data types. ATP12A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP12A RNA expression–survival associations across cancer types. High ATP12A expression shows unfavorable associations in UVM, DLBC and BLCA, but favorable associations in CESC, LIHC and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP12A RNA expression.
This table summarizes ATP12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ATP12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP12A shows lower tumor expression in KIRC, KIRP, KICH, LUAD and HNSC and higher tumor expression in UCEC. The KIRC box plot shows higher ATP12A RNA expression in normal versus tumor tissue (log2 FC = −3.240, t-test p < 0.001).
This table shows molecular features associated with ATP12A in patient tissues and cancer cell lines. In patient samples, ATP12A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
